ClinicalTrials.gg
CompletedNCT06619392Updated Mar 5, 2025

A Single Dose Escalation Trial of HRS-2129 in Healthy Subjects

A Phase 1 interventional study of HRS-2129 and HRS-2129 Placebo in Pain, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pain · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
12th of 15
44 · median 96
Started
2024
with 1 other
Phase 1
7 of 15
none open now
Registered
12th of 15
by date

Among the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd., this one is the 12th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 1, and was the 12th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Pain, anywhere →

Where they have run

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics in healthy subjects, and to evaluate the food effect on pharmacokinetics of HRS-2129.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 55 years old (inclusive);
  2. Body weight: ≥ 50 kg for male and ≥ 45 kg for female, : 19.0 \~ 28.0 kg/m2 (inclusive);
  3. Subject has no plan to give a birth, donate sperm or eggs from signing the form to 6 months after last dose;
  4. Female subjects: non-pregnant or non-lactating;
  5. The skin to receive pain stimuli has no wound or derma disease.
  6. Subject who is willing to accept cold pain test.
  7. Subject who voluntarily signs the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Subject who suffers from clinical acute and chronic diseases of circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities;
  2. Subject with the following abnormalities: , alanine aminotransferase, total , or serum creatine value exceeds the , > 450 ms, hyperpotassemia or hypopotassemia;
  3. Subject with a history of torsade de pointes, symptomatic ventricular arrhythmia, or personal or family history of short QT syndrome or long QT syndrome;
  4. Subject with a history of allergies to the IMP or its , or subject with allergic constitution;
  5. Subject who underwent major surgery within 6 months prior to screening, or received surgery that may significantly affect the pharmacokinetics or safety evaluation of the IMP, or who plans to undergo surgery during the study period;
  6. Subject with a medication history that inhibits or induces liver metabolism of drug has been used within 1 month before administration;
  7. Subject with vaccinated within 1 month prior to screening or plan to be vaccinated during the study;
  8. Subject who used any drugs or health products (including Chinese herbal medicines) within 7 half-lives or 14 days (whichever is longer) before administration, or who plans to receive other drug treatments during the study;
  9. Subject who has participated in clinical trials and received experimental drugs within 3 months before screening, or plans to participate in other clinical trials during this study;
  10. Donate blood/blood loss ≥ 400 mL within 3 months before screening;
  11. Subject who smoked more than 5 cigarettes per day on average within 3 months before screening;
  12. Drink more than 14 units of alcohol per week on average;
  13. Drink excessive tea, coffee or caffeinated beverages within 3 months before screening;
  14. Consume special food (such as grapefruit, grapefruit juice or food/drink containing grapefruit juice, chocolate, tobacco, alcohol, caffeine and other food or drink) within 48 hours before administration;
  15. Subject who has special requirements for diet and cannot follow a unified diet;
  16. Subject with clinical significant abnormalities in medical examination;
  17. Subject with positive tests for surface antigen, virus antibody, syphilis or antibody;
  18. Subject with a history of drug abuse or with a positive result for drug abuse test;
  19. Alcohol test result is positive;
  20. Subject who has difficulty in swallowing, or venous blood collection, or who cannot tolerate venipuncture, or who has a history of fainting of needle or blood;
  21. Subject may not be able to complete the study due to other reasons or the investigators considers that he is not suitable for inclusion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Treatment at dose level 1

    Drug: HRS-2129 · Drug: HRS-2129 Placebo

  • Experimental
    Treatment at dose level 2

    Drug: HRS-2129 · Drug: HRS-2129 Placebo

  • Experimental
    Treatment at dose level 3

    Drug: HRS-2129 · Drug: HRS-2129 Placebo

  • Experimental
    Treatment at dose level 4

    Drug: HRS-2129 · Drug: HRS-2129 Placebo

  • Experimental
    Treatment at dose level 5

    Drug: HRS-2129 · Drug: HRS-2129 Placebo

Interventions

  • HRS-2129

  • DrugHRS-2129 Placebo

    HRS-2129 Placebo

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events

    Time frame: from ICF signing date to day 28 since last dose

Secondary outcomes

  1. Pharmacokinetic parameter of HRS-2129: Cmax

    Time frame: 0 hour to 216 hour after administration

  2. Pharmacokinetic parameter of HRS-2129: AUC0-t

    Time frame: 0 hour to 216 hour after administration

  3. Pharmacokinetic parameter of HRS-2129: AUC0-inf

    Time frame: 0 hour to 216 hour after administration

  4. Pharmacokinetic parameter of HRS-2129: Tmax

    Time frame: 0 hour to 216 hour after administration

  5. Pharmacokinetic parameter of HRS-2129: t1/2

    Time frame: 0 hour to 216 hour after administration

  6. Pharmacokinetic parameter of HRS-2129: CL/F

    Time frame: 0 hour to 216 hour after administration

  7. Pharmacokinetic parameter of HRS-2129: Vz/F

    Time frame: 0 hour to 216 hour after administration

  8. Electrocardiogram measurement: QTcF interval

    Time frame: 90 minute predose to 48 hour after administration

  9. Pain detection threshold for the Thermode Cold Test

    Time frame: 0 hour to 12 hour after administration

  10. Pain tolerance time for the Thermode Cold Test

    Time frame: 0 hour to 12 hour after administration

07

Study locations

1 site
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jan 2025, 3 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 3 months is below that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Oct 1, 2024
StartActual
Oct 17, 2024
Primary completionActual
Jan 20, 2025
CompletionActual
Jan 20, 2025
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06619392
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Oct 17, 2024
Primary completion
Jan 20, 2025
Completion
Jan 20, 2025
Last update
Mar 5, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-2129

Start the discussion